PROFILPELAJAR.COM

Atacicept

Atacicept
Clinical data
Trade namesTrutakna
Other namesatacicept-vymj
AHFS/Drugs.comtrutakna
License data
Routes of
administration		Subcutaneous
ATC code
  • none
Legal status
Legal status
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC3104H4788N856O950S44
Molar mass70708.13 g·mol−1

Atacicept, sold under the brand name Trutakna, is a medication used for the treatment of proteinuria in immunoglobulin A nephropathy.[1] It is given via subcutaneous injection (under the skin).[2] Atacicept was developed by Merck KGaA.[3]

Atacicept was approved for medical use in the United States in July 2026.[4] Atacicept is the first medication that targets both B-cell activating factor and a proliferation-inducing ligand (APRIL), which are involved in survival and maturation of certain immune cells.[2] This in turn decreases production of the abnormal immunoglobulin A antibody.[2]

Medical uses

Atacicept is indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk for disease progression.[2]

Immunoglobulin A nephropathy is a serious kidney disease that occurs when an abnormal form of an immunoglobulin A antibody builds up in the kidneys, causing kidney inflammation and damage.[2] This kidney damage can cause protein to leak from the blood into the urine (proteinuria) and loss of kidney function over time that may progress to kidney failure.[2]

Pharmacology

Mechanism of action

Atacicept is a fusion protein of the human transmembrane activator, calcium modulator, and cyclophilin ligand interactor (TACI) receptor and the Fc portion of human IgG1 (TACI Fc), which has been modified to reduce Fc receptor-mediated effector functions.[1] This blood-soluble protein can bind two cytokines that regulate maturation, function, and survival of B cells – B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), with the constant region of immunoglobin.[5]

Atacicept is thought to selectively impair mature B cells and plasma cells with less impact on progenitor cells and memory B cells.[6]

Manufacturing

Atacicept is produced by recombinant DNA technology in Chinese hamster ovary cells. [1]

History

The efficacy and safety of atacicept were evaluated in a randomized, double-blind, placebo-controlled clinical trial (NCT04716231) in adult participants with biopsy-confirmed IgA nephropathy.[2] Participants were randomly assigned to either atacicept 150 mg injected subcutaneously once weekly or placebo.[2]

Society and culture

Atacicept was approved for medical use in the United States in July 2026.[7] The US Food and Drug Administration (FDA) granted the application for atacicept priority review and breakthrough therapy designations.[2] The FDA granted the approval of Trutakna to Vera Therapeutics.[2]

Names

Atacicept is the international nonproprietary name.[8]

Atacicept is sold under the brand name Trutakna.[1]

References

  1. ^ a b c d e "Trutakna- atacicept injection, solution". DailyMed. 6 July 2026. Retrieved 20 July 2026.
  2. ^ a b c d e f g h i j "FDA Approves New Treatment to Reduce Proteinuria in Adults with Primary Immunoglobulin A Nephropathy". U.S. Food and Drug Administration (FDA). 7 July 2026. Retrieved 11 July 2026. Public Domain This article incorporates text from this source, which is in the public domain.
  3. ^ "Merck KGaA, Darmstadt, Germany, Announces Out-Licensing Agreement for Investigational Atacicept with Vera Therapeutics" (Press release). Merck KGaA. 9 November 2020. Retrieved 11 July 2026 – via EMD Group.
  4. ^ "Novel Drug Approvals for 2026". U.S. Food and Drug Administration (FDA). 29 July 2026. Retrieved 4 August 2026.
  5. ^ Hartung HP, Kieseier BC (July 2010). "Atacicept: targeting B cells in multiple sclerosis". Therapeutic Advances in Neurological Disorders. 3 (4): 205–16. doi:10.1177/1756285610371146. PMC 3002656. PMID 21179612.
  6. ^ Nestorov I, Munafo A, Papasouliotis O, Visich J (April 2008). "Pharmacokinetics and biological activity of atacicept in patients with rheumatoid arthritis". Journal of Clinical Pharmacology. 48 (4): 406–17. doi:10.1177/0091270008315312. PMID 18303125. S2CID 11540779.
  7. ^ "Vera Therapeutics Receives FDA Accelerated Approval for Trutakna for Adult Patients with Primary IgA Nephropathy" (Press release). Vera Therapeutics. 7 July 2026. Retrieved 11 July 2026 – via GlobeNewswire.
  8. ^ World Health Organization (2007). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 57". WHO Drug Information. 21 (1). hdl:10665/74004.

Further reading

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.